What price did the CTTH insider pay per share in this transaction?

The reporting person purchased 10,100 CTTH shares at a price of $0.045 per share on September 22, 2026. The filing describes this as a purchase in an open market or private transaction.

CTT Pharma CEO buys 10,100 shares at $0.045

Q: Is the CTTH Form 4 transaction a buy or a sell?

The Form 4 reports a buy transaction. The CEO, as the reporting person, purchased 10,100 CTTH shares in an open market or private transaction, bringing direct holdings to 1,056,800 shares after the trade.

CTT Pharmaceutical Holdings, Inc. (CTTH) reported that its CEO, as a director and officer of the company, purchased 10,100 shares of CTTH on September 22, 2026 in an open market or private transaction at $0.045 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

CTT Pharmaceutical Holdings, Inc. (CTTH) reported that its CEO, as a director and officer of the company, purchased 10,100 shares of CTTH on September 22, 2026 in an open market or private transaction at $0.045 per share. Following this transaction, the reporting person directly holds 1,056,800 shares of CTTH common stock. No Rule 10b5-1 trading plan is indicated.

Insider Trade Summary

Net Buyer: 10,100 shares

Net Buy 1 txn

Insider CTT PHARMACEUTICAL HOLDINGS, INC.

Role CEO

Bought 10,100 shs ($454.50)

Type	Security	Shares	Price	Value
Purchase	CTTH	10,100	$0.045	$454.50

Holdings After Transaction: CTTH — 1,056,800 shares (Direct)

Key Figures

Shares purchased: 10,100 shares Purchase price per share: $0.045 per share Shares held after transaction: 1,056,800 shares

3 metrics

Shares purchased 10,100 shares Non-derivative purchase on September 22, 2026

Purchase price per share $0.045 per share Open market or private transaction on September 22, 2026

Shares held after transaction 1,056,800 shares Direct ownership following September 22, 2026 purchase

Key Terms

open market or private transaction, direct ownership

2 terms

open market or private transaction financial

"Purchase in open market or private transaction"

direct ownership financial

"the reporting person directly holds 1,056,800 shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CTTH report on this Form 4?

CTT Pharmaceutical Holdings, Inc. reported that its CEO purchased 10,100 CTTH shares on September 22, 2026 in an open market or private transaction at $0.045 per share, increasing the reporting person’s direct ownership.

How many CTTH shares does the reporting person hold after this transaction?

After the reported purchase, the reporting person directly owns 1,056,800 CTTH shares. This figure represents the total direct holdings following the September 22, 2026 transaction disclosed on the Form 4.

Was the CTTH insider trade made under a Rule 10b5-1 trading plan?

No. The filing indicates the Rule 10b5-1 checkbox is not marked, so the September 22, 2026 purchase of 10,100 CTTH shares at $0.045 per share is not reported as being made under a Rule 10b5-1 trading plan.

Is the CTTH Form 4 transaction a buy or a sell?

The Form 4 reports a buy transaction. The CEO, as the reporting person, purchased 10,100 CTTH shares in an open market or private transaction, bringing direct holdings to 1,056,800 shares after the trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/22/2026 - 10:16 AM Accepted by SEC EDGAR 09/22/2026 - 10:15 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CTT PHARMACEUTICAL HOLDINGS, INC.

(Last)

(First)

(Middle)

1646 W. SNOW AVE SUITE 138

(Street)

TAMPA

FLORIDA

33606

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CTT PHARMACEUTICAL HOLDINGS, INC. [ CTTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
CTTH	09/22/2026		P		10,100	A	$0.045	1,056,800	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	Ryan Khouri	09/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

CTT Pharma CEO buys 10,100 shares at $0.045

Rhea-AI Filing Summary

Positive

Negative